IN THE UNITED STATES DISTRICT COURT PECEIVED FOR THE DISTRICT OF SOUTH CAROLINA CONFLECTON, SC CHARLESTON DIVISION

Z61.	<u> 30 d</u>	T -	A	9:	28	

IN RE: LIPITOR (ATORVASTATIN CALCIUM) MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION)) MDL No. 2:14-mn-02502-RMG)) CASE MANAGEMENT) ORDER NO. 46	
) This Document Relates to:	
) <i>Karmen Ambarchian, et al. v. Pfizer Inc.</i> , 2:15-cv-1911-RMG	
) Mariam Ayrapetyan, et al. v. Pfizer Inc., 2:15-cv-1913-RMG	
	Larisa Galstian, et al. v. Pfizer Inc., 2:15- cv-1912-RMG	

ORDER APPROVING JOINT STIPULATION

In light of the Joint Stipulation regarding Defendant Pfizer Inc.'s ("Pfizer") Motion to Dismiss Plaintiffs' Cases for Failure to Comply with Discovery Obligations ("Stipulation," Dkt. No. 1122), and for good cause shown, it is hereby ORDERED, with respect to the Plaintiffs in *Karmen Ambarchian, et al. v Pfizer Inc., et al.*, case number 2:15-cv-1911-RMG, *Mariam Ayrapetyan, et al. v. Pfizer Inc., et al.* case number 2:15-cv-1913-RMG, and *Larisa Galstian, et al. v. Pfizer Inc., et al.*, case number 2:15-cv-1913-RMG, and *Larisa Galstian, et al. v. Pfizer Inc., et al.*, case number 2:15-cv-1913-RMG, and *Larisa Galstian, et al. v. Pfizer Inc., et al.*, case number 2:15-cv-1913-RMG, and *Larisa Galstian, et al.*, *v. Pfizer Inc., et al.*, case number 2:15-cv-1913-RMG, and *Larisa Galstian, et al.*, *v. Pfizer Inc., et al.*, case number 2:15-cv-1913-RMG, and *Larisa Galstian, et al.*, *v. Pfizer Inc., et al.*, case number 2:15-cv-1913-RMG, and *Larisa Galstian, et al.*, *v. Pfizer Inc., et al.*, case number 2:15-cv-1913-RMG, and *Larisa Galstian, et al.*, *v. Pfizer Inc., et al.*, case number 2:15-cv-1913-RMG, and *Larisa Galstian, et al.*, *v. Pfizer Inc., et al.*, case number 2:15-cv-1912-RMG ("Plaintiffs"), that:

- 1. The Plaintiffs' time to respond to provide compliant PFSs and other mandatory disclosures is extended to October 26, 2015;
- The Plaintiffs' time to respond to Pfizer's Motion to Dismiss is extended to October 31, 2015;
- 3. With respect to the Plaintiffs who provide complete and compliant PFSs and other Mandatory disclosures by October 26, 2015, Pfizer's Motion to Dismiss will be

withdrawn without prejudice to Pfizer's rights to identify deficiencies or omissions in the PFSs or disclosures provided by the Plaintiffs and shall retain the right to make an appropriate motion if such deficiencies or omissions are not timely cured;

- 4. With respect to the Plaintiffs who fail to provide complete and compliant PFSs and other mandatory disclosures by October 26, 2015, and who do not voluntarily dismiss their actions by October 26, 2015, Pfizer's Motion to Dismiss will proceed as to those plaintiffs as of October 27, 2015;
- 5. The Plaintiffs will not seek or move for remand of their actions to California state court and will remain coordinated in MDL No. 2:14-mn-02502-RMG;
- 6. To the extent any of the Plaintiffs seek a voluntary dismissal of their claims, he or she will agree to all the terms of dismissal required by the Court in CMO 12, including an agreement that any re-filing of the action will be in federal court.

AND IT IS SO ORDERED.

Hon. Richard Mark Gergel United States District Judge

September $\underline{\mathcal{VS}}$, 2015 Charleston, South Carolina